- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Gerald J. Flattmann, Jr.
News 27 results
Recognition
June 1, 2022
Chambers USA 2022 Recognizes 188 K&S Lawyers and 75 K&S Practice Groups as Leaders in Their Fields
In the News · Source: Law360
Recognition
October 13, 2021
Benchmark Litigation Recognizes King & Spalding as a Leading Litigation Firm
Recognition
October 5, 2021
LMG Life Sciences Recognizes King & Spalding With Multiple Rankings in its 2021 Guide
Events 4 results
Webinar
November 9, 2021
King & Spalding Pharmaceutical University 2021
Speaking Engagement
April 27, 2021
Vanessa Yen, Evan Diamond, Gerald Flattmann to Speak at American Conference Institute’s 2021 Paragraph IV Disputes Master Symposium
Webinar
November 10, 2020
13th Annual King & Spalding Medical Device Summit
Conference
November 12, 2019
12th Annual King & Spalding Pharmaceutical University
Insights 2 results
Article
March 11, 2021
Biden Administration - What's Ahead for the Life Sciences Industry?
Client Alert
February 12, 2021
GSK v. Teva and Induced Infringement by AB-Rated Generics: Where are we now?